Pediatric Oncology Drug Pipeline — PatSnap Eureka
Pediatric Oncology Drug Pipeline: DIPG, Medulloblastoma & Neuroblastoma Targeted Therapies
Diffuse intrinsic pontine glioma remains almost universally fatal. High-risk neuroblastoma carries a five-year survival rate below 50%. Explore the patent-evidenced targeted therapy landscape — from TGF-β2 ASOs to PARP inhibitors and RNA delivery — with PatSnap Eureka.
Three Malignancies, Multiple Molecular Axes
Diffuse intrinsic pontine glioma (DIPG), medulloblastoma, and neuroblastoma collectively represent among the most therapeutically challenging pediatric malignancies. DIPG remains almost universally fatal, while high-risk neuroblastoma carries a five-year survival rate below 50%. Retrieved patent and literature evidence identifies distinct molecular drivers for each indication.
For DIPG, TGF-β2 is identified as a high-priority driver. TGFB2 mRNA expression is significantly and positively correlated with worse overall survival (OS) and progression-free survival (PFS) in pediatric DIPG patients carrying H3K27M mutations, based on data from 41 pediatric patients. A separate patent covers pleiotrophin (PTN) / PTPRZ1 signaling, disclosing that PTPRZ1 mediates DIPG cell invasion toward the subventricular zone (SVZ).
For medulloblastoma, retrieved results identify RNA-based payload delivery via 3E10 antibody-polynucleotide complexes and miR-199b-5p as both a histopathological marker and a therapeutic target. For neuroblastoma — the most frequently represented indication in the dataset — key findings include biomarkers MAPT, CASP3, and CASP9 as prognostic survival indicators, alongside the long noncoding RNA NBAT1 as a suppressor of aggressive neuroblastoma biology. Learn more about life sciences IP intelligence on PatSnap.
The World Health Organization classifies these tumors among the most urgent unmet needs in pediatric oncology, underscoring the importance of tracking emerging IP signals in this space.
Eight Targeted Approaches Across Three Indications
Patent evidence identifies distinct mechanistic clusters spanning RNA suppression, small molecules, antibody conjugates, and immunotherapy — each addressing different aspects of pediatric tumor biology.
Antisense Oligonucleotides Targeting TGF-β2 (OT-101)
A 2025 CN patent discloses ASOs targeting TGF-β2 mRNA in DIPG and H3K27M-mutant GBM. Compound OT-101 is specifically named, with clinical tumor-volume reduction data presented including waterfall plots showing complete or partial response. The filing also discloses a novel intracranial infusion device for CNS drug delivery via convection-enhanced or intrathecal routes.
Zhao Wangyu, 2025, CN Clinical SignalPleiotrophin / PTPRZ1 Pathway Inhibition
A Stanford University active US patent (2019) discloses that immunodepletion of PTN from SVZ-conditioned medium reduces DIPG cell invasion, and that PTPRZ1 knockdown decreases tumor engraftment in SU-DIPG-XIII FL cells. Co-expressed SVZ proteins SPARC, SPARCL1, and HSP90B are identified, with PTN/PTPRZ1 as the primary therapeutic axis. Development stage: preclinical.
Stanford University, 2019, US PreclinicalPARP Inhibition — AstraZeneca Azaquinolone Compounds
A pending Brazilian patent (2024) from AstraZeneca discloses substituted azaquinolone compounds with PARP inhibitor activity for treatment of brain tumors and neuroblastoma, extending the established adult oncology modality (olaparib/rucaparib) into the pediatric setting. This may leverage DNA damage repair vulnerabilities accentuated by H3K27M or MYCN amplification contexts.
AstraZeneca AB, 2024, BR Preclinical / IND-Enabling3E10 Antibody-Polynucleotide Conjugates for CNS Tumors
A Yale University pending CN patent (2024) discloses complexes between the 3E10-D31N antibody and therapeutic polynucleotides (including 3p-hpRNA, an innate immune activator). In vivo data in orthotopic medulloblastoma (DAOY) models show CNS accumulation of fluorescently labeled 3E10-D31N and significant tumor growth inhibition versus temozolomide controls.
Yale University, 2024, CN Preclinical (In Vivo)Patent Evidence Across Modalities & Assignees
Visual summaries of the therapeutic modality distribution and key molecular targets identified across the DIPG, medulloblastoma, and neuroblastoma patent dataset.
Patent Records by Therapeutic Modality
Neuroblastoma prognostic classifiers dominate the dataset (5 records); all other modalities are represented by 1 patent each, reflecting early-stage IP activity.
Assignee Landscape — Academic vs. Commercial IP
Activity is mixed between academic institutions (Stanford, Yale, University of South Florida, Ghent University) and commercial entities (AstraZeneca, Immatics, Chimerix, Advanced Accelerator Applications).
Development Stage Signal by Modality
OT-101 (TGF-β2 ASO) is the only modality with direct clinical response data in the dataset; all others are at preclinical or stratification stages.
Key Molecular Targets by Indication
Each indication has distinct primary molecular targets identified across retrieved patent evidence, with neuroblastoma showing the broadest biomarker characterisation.
Emerging Directions & Strategic Implications
Retrieved patent evidence signals five combination and emerging strategies, alongside key strategic implications for developers, IP strategists, and investors.
TGF-β2 ASO + Standard Cancer Agents (DIPG)
The 2025 CN patent explicitly states that TGF-β2 ASO agents "can be used in combination with cancer drugs," positioning OT-101 as combinable with established glioma therapeutics. The filing also introduces a novel intracranial infusion delivery device, signaling engineering innovation alongside molecular targeting.
3E10-RNA Payload + Immune Activation (Medulloblastoma)
The Yale CN patent (2024) discloses that cD31N/3p-hpRNA complexes outperform temozolomide monotherapy in orthotopic medulloblastoma models. Related disclosures suggest signals toward immuno-oncology combination strategies for CNS tumors, including checkpoint inhibition combinations.
Blood-Brain Barrier: The Central Delivery Challenge
Retrieved innovations consistently address CNS delivery through novel ASO intracranial infusion devices, antibody-mediated CNS trafficking (3E10), and CNS-penetrant small molecule design (ONC-206). Tumor biology solutions are insufficient without accompanying delivery solutions.
TGF-β2/PTPRZ1 Axis: A DIPG-Specific IP Opportunity
Stanford's active PTN/PTPRZ1 patent and the TGF-β2 ASO filings are distinct mechanistic clusters with limited apparent overlap. Developers and IP strategists should note these as potentially non-competing therapeutic axes that could support combination IP construction.
Who Is Filing in Pediatric Oncology Targeted Therapy?
Nine organisations and individuals are identified across the dataset, spanning academic institutions and commercial pharmaceutical and biotech entities. Explore the full competitive landscape via PatSnap's IP analytics platform.
| Assignee | Jurisdiction / Year | Modality | Indication | Type |
|---|---|---|---|---|
| Zhao Wangyu | CN · 2025 | TGF-β2 ASO (OT-101) | DIPG / DMG | Clinical Signal |
| Stanford University | US · 2019 | PTN / PTPRZ1 Pathway | DIPG / High-Grade Glioma | Academic IP |
| AstraZeneca AB | BR · 2024 | PARP Inhibition | Brain Tumors / Neuroblastoma | Commercial IP |
| Yale University | CN · 2024 | 3E10 Antibody-RNA Conjugate | Medulloblastoma | Academic IP |
| Immatics Biotechnologies GmbH | PL · 2020 | Peptide Immunotherapy | Brain & Neuronal Tumors | Commercial Biotech |
| Chimerix, Inc. | BR · 2024 | ONC-206 (CNS Small Molecule) | CNS Neoplasms | Clinical-Stage Biotech |
| Advanced Accelerator Applications | ES · 2017 | miR-199b-5p Modulation | Medulloblastoma | Commercial (Novartis sub.) |
| University of South Florida | WO · 2020 | MAPT / CASP3 / CASP9 Biomarkers | Neuroblastoma | Academic IP |
| Ghent University / Speleman | WO/EP · 2010–11 | Multigene Prognostic Signature | Neuroblastoma | Academic IP |
Track New Filings from These Assignees in Real Time
PatSnap Eureka monitors 120+ countries' patent offices and alerts you to new activity from key players in your indication. See how PatSnap customers use competitive intelligence to stay ahead.
What Has Reached the Clinic or IND Stage?
The 2025 CN patent filing for OT-101 explicitly references objective response data from high-grade glioma patients treated with OT-101 monotherapy, including swimmer plots depicting duration of complete response or partial response (CR/PR), and waterfall plots of maximum log10 tumor volume reduction. This constitutes the only direct clinical signal within the dataset, though formal trial registration details are not enumerated in the retrieved text.
The Chimerix BR patent (2024) references treatment of patients with primary and recurrent CNS neoplasms consistent with clinical or IND-enabling activity for ONC-206; however, the filing does not include explicit patient outcome data in the retrieved text. The ClinicalTrials.gov registry provides additional context on active pediatric neuro-oncology trials beyond this patent dataset.
Immatics' active PL patent (2020) references vaccine compositions for eliciting anti-tumor immune responses in brain and neuronal tumors. Immatics has active clinical-stage programs in peptide vaccines; however, the retrieved text does not itself specify clinical trial data for pediatric brain tumors.
For neuroblastoma, retrieved patents (prognostic classifiers, MAPT/CASP3/CASP9 biomarkers) are preclinical and stratification-focused rather than reporting clinical intervention outcomes. No medulloblastoma-specific clinical signals are present in the dataset. The National Institutes of Health maintains literature databases that complement patent-based intelligence for full pipeline mapping. Explore PatSnap's full platform for integrated patent and literature search.
Pediatric Oncology Drug Pipeline — key questions answered
High-risk neuroblastoma carries a five-year survival rate below 50%, making it one of the most therapeutically challenging pediatric malignancies.
OT-101 is an antisense oligonucleotide (ASO) that suppresses TGF-β2 mRNA expression in DIPG and H3K27M-mutant GBM. A 2025 patent filing cites tumor volume reduction data in high-grade glioma patients receiving OT-101 monotherapy, including waterfall plots showing complete or partial response, with intracerebral infusion as the delivery route.
PTPRZ1 (a receptor-type protein tyrosine phosphatase) mediates DIPG cell invasion toward the subventricular zone (SVZ). Knockdown of PTPRZ1 significantly decreases tumor engraftment and invasion in DIPG models using the SU-DIPG-XIII FL cell line, as disclosed in a Stanford University active US patent.
The 3E10-D31N antibody crosses the blood-brain barrier and traffics to CNS tumors, enabling delivery of immunostimulatory RNA (3p-hpRNA) specifically to medulloblastoma. In vivo data in orthotopic medulloblastoma (DAOY) models show significant tumor growth inhibition by cD31N/3p-hpRNA complexes versus temozolomide controls.
Key biomarkers include MAPT, CASP3, and CASP9, where lower expression correlates with shorter overall survival. Additionally, elevated expression of DLK1, PRSS3, and SLIT3 are identified as predictors of poor outcome in neuroblastoma. The long noncoding RNA NBAT1 acts as a suppressor of aggressive neuroblastoma biology.
AstraZeneca's disclosed azaquinolone PARP inhibitors extend an established oncology modality (already validated in BRCA-mutant adult cancers) into pediatric brain tumors and neuroblastoma, presumably leveraging DNA damage repair vulnerabilities that may be accentuated by H3K27M or MYCN amplification contexts. The filing is patent-based at an apparent preclinical/IND-enabling stage.
Still have questions? Let PatSnap Eureka search the full patent and literature landscape for you.
Ask Eureka Your Pipeline QuestionAccelerate Your Pediatric Oncology Research with AI-Native Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from DIPG molecular targets to neuroblastoma biomarker-to-therapy translation.
References
- Compositions and Methods for CNS Diseases — Zhao Wangyu, 2025, CN [Patent]
- Targeting Pleiotrophin Signaling to Limit High-Grade Glioma Invasion — Stanford University, 2019, US [Patent]
- Treatment Methods for Brain Tumors and Neuroblastomas — AstraZeneca AB, 2024, BR [Patent]
- Compositions and Methods for Treating Cancer — Yale University, 2024, CN [Patent]
- Personalized Immunotherapy Against Several Neuronal and Brain Tumors — Immatics Biotechnologies GmbH, 2020, PL [Patent]
- Uses and Methods for Primary Recurrent CNS Neoplasms — Chimerix, Inc., 2024, BR [Patent]
- Biomarkers of Low Grade Glioma and Pediatric Neuroblastoma — University of South Florida, 2020, WO [Patent]
- Selections of Genes and Methods for Diagnosis, Prognosis and Targeting Therapy of Neuroblastoma — Greer, Braden T., 2006, WO [Patent]
- Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Neuroblastoma — Khan, Javed, 2009, US [Patent]
- Neuroblastoma Prognostic Multigene Expression Signature — Speleman, Franki, 2010, WO [Patent]
- Neuroblastoma Prognostic Multigene Expression Signature — Ghent University, 2011, EP [Patent]
- Neuroblastoma Prognostic Multigene Expression Signature — Speleman, Franki, 2011, US [Patent]
- Use of MicroRNA-199b-5p in Medical and Diagnostic Field — Advanced Accelerator Applications S.A., 2017, ES [Patent]
- Brain Tumor Diagnosis and Outcome Prediction — Golub, Todd R., 2002, US [Patent]
- Fighting Neuroblastomas with NBAT1 — Department of Medical Genetics, 2015 [Paper]
- World Health Organization — Childhood Cancer Classification and Burden
- National Cancer Institute — Neuroblastoma Treatment (PDQ)
- ClinicalTrials.gov — Pediatric Neuro-Oncology Active Trials Registry
- National Institutes of Health / PubMed — Pediatric Oncology Literature
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only — it should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.